Ulotaront, a novel antipsychotic under investigation for schizophrenia and adjunctive treatment for major depressive disorder31 and generalized anxiety disorder,32 primarily exerts its antipsychotic efficacy as a TAAR1 agonist but also has 5HT1A agonist activity, which may improve depression and anxiety.33 Here, TAAR1 is linked to depressive symptom measurement.